Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
Abcam’s new premium-grade bioactive proteins are highly-active growth factors and cytokines manufactured and designed to meet the specific needs of cell culture, including cell and gene therapy and regenerative medicine.
Ida Emilie Steinmark, PhD | Apr 26, 2023 | 3 min read
In a bid to address safety concerns about immune reactions during treatment with CRISPR-based therapeutics, a new technique speeds up how quickly the body destroys the DNA-cutting enzyme Cas9.
In just 16 months, physicians went from identifying a novel rare disease in three-year-old Marley to successfully treating her with a drug previously used to treat African sleeping sickness and pediatric cancer.